SWAN Isotopen

SWAN Isotopen AG operates a commercial radiopharmaceuticals production
facility on the campus of the University Hospital Bern.

Learn more
Production
SWAN Isotopen AG operates a commercial radiopharmaceuticals production facility on the campus of the University Hospital Bern.
Europe
The facility is one of the most modern radiopharmaceutical production sites in Europe situated in the heart of a renowned University Hospital.
Radiopharmaceuticals
The company produces and distributes GMP radiopharmaceuticals used for molecular imaging/diagnosis.
Development
In close collaboration with the University of Bern (radiochemistry and high energy physics research groups) the company participates in the development of targeted radio therapeutics.
Oncology
SWAN Isotopen AG’s products find their application mostly in the field of oncology. They are used for tumor diagnosis and therapy monitoring and thus allow the perfect adaptation of treatments to the patients’ needs.
Transport
SWAN Isotopen AG is one of the few companies in Switzerland and the only company in the Espace Mittelland to offer a transport service for radioactive materials.

News

Show more

Information for professionals – PET Tracers

Our products are manufactured according to the international GMP guidelines (Good Manufacturing Practices). They are distributed according to the international GDP guidelines (Good Distribution Practices).

These precautions guarantee your patients the highest quality products.

FDG Flu-SWAN

SMC MA-no. : 61546
Production days: Monday to Friday

Technical information

Flu-SWAN, a tracer for PET (positron emission tomography), is an isotonic [18F]-Fludeoxyglucose solution calibrated at 185 MBq/ml.

It is a ready-to-use radiodiagnostic for direct application.

Flu-SWAN has a physiological pH and, in addition to [18F] Fludeoxyglucose, contains only sodium chloride and 0.5% ethanol. It contains no buffer solution; the ethanol in the solution stabilizes the product with respect to a possible radiolysis. The shelf-life of the product is 12 hours after EOS (end of synthesis).

SWAN-PSMA-1007

SMC MA-no. : 67370
Production days: Monday + Wednesday

Technical information

SWAN-PSMA-1007 is a radiodiagnostic agent for the imaging of pathological changes by positron emission tomography (PET), which are associated with an increased expression of prostate specific membrane antigen (PSMA). It can be used to visualise tumour foci in patients with adenocarcinoma of the prostate (prostate carcinoma).

It is a ready-to-use radiodiagnostic for direct application.

FCH SWAN-Cholin

SMC MA-no.: 66087
Production days: upon request

Technical information

SWAN-Cholin is a radiopharmaceutical for the assessment of the local tumor extent of a proven prostate carcinoma by PET (positron emission tomography). It is a radioactive 18F-labeled analog to natural choline, which is a substrate for the synthesis of cell membrane components.

SWAN-Choline is a ready-to-use radiodiagnostic for direct application.

1 ml solution for injection contains 222 MBq/ml of the active ingredient [18F] Fluoromethylcholine at the time of calibration. The included excipients are sodium chloride and water for injections. It contains no buffer solution or preservative. The shelf life of the product is 10 hours after EOS (end of synthesis).

FBB Neuraceq

SMC MA-no.: 66210
Delivery days: upon request

Technical information

Neuraceq is a radiodiagnostic used to visualize the density of neuritic β-amyloid plaques in the brain of adult patients with cognitive impairment who are being examined for Alzheimer’s disease (AK) or other causes of cognitive impairment.

Neuraceq should be used in conjunction with a clinical examination only.

1 ml solution for injection contains 300 MBq Florbetaben (18F) at the time of calibration indicated on the package. The shelf life of the product is 10 hours after EOS (end of synthesis).

Transport of dangerous goods Class 7

SWAN Isotopen AG is one of the few companies in Switzerland and the only company in the Espace Mittelland to offer a transport service for radioactive materials. As a producer of short-lived radiopharmaceuticals, we know how important an absolutely reliable transport service is for suppliers and customers.

We offer:

  • Our own professionally equipped fleet
  • Radiopharmaceutical transports
  • Transport of dangerous goods Class 7
  • Pharmaceutical transports

Dangerous goods safety adviser class 7

Do you need a dangerous goods officer for the transport of radioactive materials and you do not have your own employee who has this qualification? The law gives you the choice of leaving dangerous goods management to an external expert.

We offer:

  • Proper and legally compliant handling of your transports of radioactive
    Substances by our dangerous goods officer
Contact

Information for patients

What is nuclear medicine? What is PET-CT? What is PET-CT for cancer follow-up ?
These and other questions are answered in the following videos.

Show more

About us

We are an independent company specializing in the production of radiopharmaceuticals for nuclear medicine. We develop new diagnostics in close cooperation with research groups in nuclear medicine and high energy physics at the University of Bern.

Dr. med. Konrade
von Bremen

CEO / Management

Peter Huggler

CFO / Management

Team SWAN

Board

  • President: Dr. oec. Urs Birchler, former president of the Inselspital
  • Vicepresident: Prof. Dr. Christian Leumann, Rector University of Bern
  • Prof. Dr. med. Martin Fiedler, Medical Director Inselspital

 

  • Prof. Dr. med. Daniel Aebersold, Clinic Director, University Hospital for
    Radio-Oncology, Inselspital
  • Peter Kappert, Chairman of the Board of Directors PET Diagnostik Bern AG

Company history

  • 2020
    FBB Neuraceq™ BAG Duty to provide benefits (health insurance companies reimbursement approved)
  • 2019
    SWAN-PSMA-1007 temporary market approval received and 1st batch produced and delivered
  • 2018
    Flu-2-Swan
  • 2017
    FBB Neuraceq™ Market approval received
  • 2016
    FCH SWAN-Cholin Market approval for PET diagnosis of prostate cancer and 1st batch produced and delivered
  • 2013
    • SWAN Isotopen AG becomes a fully accredited radiopharmaceutical company on the Swiss market
    • FDG Flu-SWAN market approval and 1st batch produced and delivered
    • Offer transport of dangerous goods for third parties

 

  • 2012
    Move into the 5-storey SWAN building of SWAN Isotopen AG. On the upper two floors is the ward for palliative and nuclear medicine, on the 1st floor offices and on the ground floor and basement the production
  • 2011
    • Installation Cyclotron
    • The swissHADRON foundation was established by SWANtec Holding
  • 2009
    Ground-breaking ceremony
  • 2008
    Foundation of SWAN Hadron AG as subsidiary of SWANtec Holding AG
  • 2007
    Foundation of SWANtec Holding AG in December 2007 by the Inselspital Foundation together with private strategic shareholders. It comprises two subsidiaries: SWAN Isotopen AG and SWAN Hadron AG.Dr. med. Konrade von Bremen, CEO, was significantly involved in the development and establishment of the SWAN Group.

Jobs

At the moment we do not have an open position

Send us a message


Address

SWAN Isotopen AG
SWAN-Haus, Inselspital
Freiburgstrasse 38
CH-3010 Bern

Tel. +41 31 384 00 40
Fax: +41 31 384 00 41

info@swantec.ch